Literature DB >> 31948942

An ABC Transporter Drives Medulloblastoma Pathogenesis by Regulating Sonic Hedgehog Signaling.

Juwina Wijaya1, BaoHan T Vo2, Jingjing Liu3, Beisi Xu3, Gang Wu3, Yao Wang1, Junmin Peng4,5, Jin Zhang6, Laura J Janke7, Brent A Orr7, Jiyang Yu3, Martine F Roussel2, John D Schuetz8.   

Abstract

Mutations in Sonic hedgehog (SHH) signaling promote aberrant proliferation and tumor growth. SHH-medulloblastoma (MB) is among the most frequent brain tumors in children less than 3 years of age. Although key components of the SHH pathway are well-known, we hypothesized that new disease-modifying targets of SHH-MB might be identified from large-scale bioinformatics and systems biology analyses. Using a data-driven systems biology approach, we built a MB-specific interactome. The ATP-binding cassette transporter ABCC4 was identified as a modulator of SHH-MB. Accordingly, increased ABCC4 expression correlated with poor overall survival in patients with SHH-MB. Knockdown of ABCC4 expression markedly blunted the constitutive activation of the SHH pathway secondary to Ptch1 or Sufu insufficiency. In human tumor cell lines, ABCC4 knockdown and inhibition reduced full-length GLI3 levels. In a clinically relevant murine SHH-MB model, targeted ablation of Abcc4 in primary tumors significantly reduced tumor burden and extended the lifespan of tumor-bearing mice. These studies reveal ABCC4 as a potent SHH pathway regulator and a new candidate to target with the potential to improve SHH-MB therapy. SIGNIFICANCE: These findings identify ABCC4 transporter as a new target in SHH-MB, prompting the development of inhibitors or the repurporsing of existing drugs to target ABCC4. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 31948942     DOI: 10.1158/0008-5472.CAN-19-2054

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

Review 1.  The human ATP-binding cassette (ABC) transporter superfamily.

Authors:  Michael Dean; Karobi Moitra; Rando Allikmets
Journal:  Hum Mutat       Date:  2022-06-22       Impact factor: 4.700

2.  The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma.

Authors:  Anand G Patel; Xiang Chen; Xin Huang; Michael R Clay; Natalia Komorova; Matthew J Krasin; Alberto Pappo; Heather Tillman; Brent A Orr; Justina McEvoy; Brittney Gordon; Kaley Blankenship; Colleen Reilly; Xin Zhou; Jackie L Norrie; Asa Karlstrom; Jiyang Yu; Dominik Wodarz; Elizabeth Stewart; Michael A Dyer
Journal:  Dev Cell       Date:  2022-04-27       Impact factor: 13.417

3.  Discovery of Novel Symmetrical 1,4-Dihydropyridines as Inhibitors of Multidrug-Resistant Protein (MRP4) Efflux Pump for Anticancer Therapy.

Authors:  Henry Döring; David Kreutzer; Christoph Ritter; Andreas Hilgeroth
Journal:  Molecules       Date:  2020-12-22       Impact factor: 4.411

4.  An ABC transporter as a potential target against SHH-Medulloblastoma: From Benchtop to Bedside.

Authors:  Jingwen Zhu; Joseph N Miller; John D Schuetz
Journal:  Oncotarget       Date:  2022-09-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.